Leash Biosciences, an artificial intelligence and machine learning (AI/ML)-native biotechnology company unleashing machine learning to solve medicinal chemistry, announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection.

The oversubscribed round was led by Springtide Ventures with participation from MetaPlanet, Top Harvest Capital, Mitsui Global Investment, MFV Partners, Recursion CEO and co-founder Chris Gibson, and Recursion co-founder Blake Borgeson.